Multiparametric In Vitro Evaluation of Cytocompatibility of 1% Strontium-Containing Nanostructured Hydroxyapatite

Abstract:

Hydroxiapatite (HA), one of the most widely employed bioceramic bone substitutes, when applied on its nanostructured form (nHA) may contribute to achieve a crystalline structure which is closer to the size and morphology of biological apatite. Furthermore, HA might also be doped with several different cations with biological effects including Sr2+. Therefore, a biomaterial based on nanostructured HA containing 1% Strontium (nSrHA) could present interesting biological properties, as strontium is described as a modulator of both osteoblast and osteoclast activities, presenting an important regulatory role on bone resorption. However, such modifications may also affect the biocompatibility of this material, which should be accessed initially by in vitro methods. Therefore, the present work aimed to evaluate the in vitro biocompatibility of 1% nSrHA discs with human primary osteoblasts through a multiparametric assay which assesses simultaneously metabolic activity (XTT assay), membrane integrity (NR test) and cell density (CVDE). Extracts of nSrHA, latex fragments (positive control), polystyrene beads (negative control) and nHA (for comparison) were prepared and exposed to 104 cells for 24h at 37°C/5% CO₂ on test plates, according to ISO 10993-5:2009, on quintuplicates. Cells exposed to unconditioned media were used as experimental control. After exposure, cells were tested for viability with a commercial multiparametric kit (In Cytotox, Xenometrix, Germany). The positive and negative controls presented the expected results, validating the assay. Both nHA and SrnHA were considered biocompatible, since the presented a cell viability after exposure statistically similar to the experimental control. In conclusion, the synthesized nSrHA discs are cytocompatible and, consequently, adequate for further in vitro tests on cell adhesion, proliferation and differentiation.

• Periodical: Key Engineering Materials (Volume 631)
• Pages: 345-350
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.631.345
• Online since: November 2014
• Authors: Daiana Reis, Daniela Silva, Juliana Côrtes, Letícia Hummel, Elena Mavropoulos, Adriana Linhares, Gutemberg Alves*
• Keywords: Biocompatibility, Hydroxiapatite, Nanostructure, Strontium

References

[1] V Lekovic, EB Kenney, M Weinlander, Han T, PR Klokkevold. A bone regenerative approach to alveolar ridge maintenance following tooth extraction. Report of 10 cases, J Periodontol 6 (1997) 563–570.

DOI: 10.1902/jop.1997.68.6.563

[2] JT Melloning. Guided tissue regeneration and endosseous dental implants, Int J Periodontics Restorative Dent 13 (1993) 109–119.

[3] J La Fontaine, et al. Regeneração Óssea Guiada. ImplantNews 5(4) (2008) 369-375.

[4] PJ Boyne, NR Sands. Combined orthodontici-surgical management of residual palato-alveolar cleft defect, Am J Orthod Dentofac Orthop 70 (1976) 20-37.

DOI: 10.1016/0002-9416(76)90258-x

[5] PJ Boyne, NR Sands,. Secondary bone grafting of residual alveolar and palatal defects,. J Oral Maxillofac Surg 30 (1972) 87-92.

[6] C. Dahlin, L. Andersson, A. Lindhe. Bone augmentation at fenestrated implants by osteopromotive membrane technique, A controlled clinical study. Clin Oral Implants Res 2(4) (1991) 159-165.

DOI: 10.1034/j.1600-0501.1991.020401.x

[7] P. S Rosen, M. A. Reynolds, and G. M. Bowers. The treatment of intrabony defects with bone grafts. Periodontology 2000 22. 1 (2000) 88-103.

DOI: 10.1034/j.1600-0757.2000.2220107.x

[8] M. D. Calasans-Maia, et al. Stimulatory Effect on Osseous Repair of Zinc-substituted Hydroxyapatite: Histological Study in Rabbit's Tibia. Key Engineering Materials. 361-363 (2008) 1269-1272.

DOI: 10.4028/www.scientific.net/kem.361-363.1269

[9] RZ. LeGeros. Properties of osteoconductive biomaterials: Calcium phosphates. Clin Orthop Relat Res 395 (2002) 81–98.

DOI: 10.1097/00003086-200202000-00009

[10] H Ohgushi, J Miyake, T Tateishi. Mesenchymal stem cells and bioceramics: strategies to regenerate the skeleton. Novartis Found Symp 249 (2003) 118–27.

DOI: 10.1002/0470867973.ch9

[11] S Sanchez-Salcedo, F Balas, I Izquierdo-Barba, M Vallet-Regi. In vitro structural changes in porous HA/beta-TCP scaffolds in simulated body fluid. Acta Biomater 5 (2009) 2738–51.

DOI: 10.1016/j.actbio.2009.03.025

[12] I. R de Lima, G. G. Alves, C. A Soriano, A. P. Campaneli, T. H. Gasparoto, , E. S. Ramos, L. A. de Sena, A. M Rossi and J. M. Granjeiro. Understanding the impact of divalent cation substitution on hydroxyapatite: an in vitro multiparametric study on biocompatibility, J Biomed Mater Res A 98 (2011).

DOI: 10.1002/jbm.a.33126

[13] E Landi, G Logroscino, L Proietti, A Tampieri, M Sandri, S Sprio. Biomimetic Mg-substituted hydroxyapatite: From synthesis to in vivo behavior, J Mater Sci Mater Med 19 (2008) 239–247.

DOI: 10.1007/s10856-006-0032-y

[14] GX Ni, WW Lu, KY Chiu, ZY Li, DY Fong, KD Luk. Strontium-containing hydroxyapatite (Sr-HA) bioactive cement for primary hipreplacement. An in vivo study, J Biomed Mater Res B Appl Biomater 77 (2006) 409–415.

DOI: 10.1002/jbm.b.30417

[15] GM Blake, MA Zivanovic, AJ McEwan, DM Ackery. Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate, Eur J Nucl Med 12(9) (1986) 447–54.

DOI: 10.1007/bf00254749

[16] E Canalis, M Hott, P Deloffre, Y Tsouderos, PJ Marie. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996; 18(6): 517–23.

DOI: 10.1016/8756-3282(96)00080-4

[17] E Shorr, AC Carter. The usefulness of strontium as an adjuvant to calcium in the remineralization of the skeleton in ma,. Bull Hosp Jt Dis Orthop Inst. 13 (1952) 59–66.

[18] A Barbara, P Delannoy, BG Denis, PJ Marie. Normal matrixmineralization induced by strontium ranelate in MC3T3–E1osteogenic cells. Metabolism, (2004).

DOI: 10.1016/j.metabol.2003.10.022

[19] E Bonnelye, A Chabadel, F Saltel, P Jurdic. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 42 (2008) 129–38.

DOI: 10.1016/j.bone.2007.08.043

[20] PJ Meunier, C Roux, E Seeman, S Ortolani, JE Badurski, TD Spector, et al. The effects of strontium ranelate on the risk of vertebra fracture in women with postmenopausal osteoporosis. N Engl J Med. 350 (2004) 459–68.

DOI: 10.1056/nejmoa022436

[21] GX Ni, KY Chiu, WW Lu, Y Wang, YG Zhang, LB Hao, et al. Strontium-containing hydroxyapatite bioactive bone cement in revision hip arthroplasty, Biomaterials 27 (2006) 4348–55.

DOI: 10.1016/j.biomaterials.2006.03.048

[22] DM Chen, YF Fu, GZ Gu. Preparation and solubility of the solid solution of strontium substituted hydroxyapatite, Chin J Biomed Eng. 20 (2003) 278–82.

[23] GX Ni, WW Lu, KY Chiu, ZY Li, DY Fong, KD Luk. Strontium containing hydroxyapatite (Sr-HA) bioactive cement for primary hip replacement: an in vivo study. J Biomed Mater Res. 77B (2006) 409–15.

DOI: 10.1002/jbm.b.30417

[24] CT Wong, WW Lu, WK Chan, KMC Cheung, KDK Luk, DS Lu, ABM Rabie, LF Deng, JCY Leong. In vivo cancellous bone remodeling on a strontium-containing hydroxyapatite (Sr-HA) bioactive cement. J Biomed Mater Res. 68A (2004) 513–21.

DOI: 10.1002/jbm.a.20089

[25] C. P. G Machado, A. V. B Pintor. M. A. K. D. A Gress. A. M, Rossi,J. M Granjeiro & M. D. C Maia,. Evaluation of strontium containing hydroxyapatite as bone substitute in sheep's tibia. Innovations Implant Journal, 5 (2010) 9-14.

[26] International Organization for Standardization. ISO 10993-5: Biological evaluation of medical devices-Part 5: Tests for in vitro cytotoxicity (2009) ISO 10993-5: (2009).

DOI: 10.2345/9781570203558